区分基于肠促胰岛素的疗法。患者教育与自我管理。
Distinguishing among incretin-based therapies. Patient education and self-management.
作者信息
Campbell R Keith, Cobble Michael E, Reid Timothy S, Shomali Mansur E
机构信息
Department of Pharmacotherapy, Washington State University College of Pharmacy, Pullman, WA, USA.
出版信息
J Fam Pract. 2010 Sep;59(9 Suppl 1):S28-30.
PMID:20824237
Abstract
Working closely with patients and providing ongoing education, ideally in conjunction with a diabetes care team, can help ensure that the best treatment options are selected for an individual patient and that the patient is capable of effective self-management.
摘要
与患者密切合作并持续提供教育，理想情况下与糖尿病护理团队协作，可以帮助确保为个体患者选择最佳治疗方案，并确保患者能够进行有效的自我管理。
相似文献
1
Distinguishing among incretin-based therapies. Patient education and self-management.
J Fam Pract. 2010 Sep;59(9 Suppl 1):S28-30.
2
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
J Fam Pract. 2010 Sep;59(9 Suppl 1):S10-9.
3
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
J Fam Pract. 2010 Sep;59(9 Suppl 1):S20-7.
4
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting.
Am J Manag Care. 2010 Aug;16(7 Suppl):S187-94.
5
Distinguishing among incretin-based therapies. Introduction.
J Fam Pract. 2010 Sep;59(9 Suppl 1):S3-4.
6
Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Ann Pharmacother. 2011 Jul;45(7-8):850-60. doi: 10.1345/aph.1Q024. Epub 2011 Jul 5.
7
[Incretin related agents for treatment of diabetes mellitus].
Nihon Naika Gakkai Zasshi. 2009 Apr 10;98(4):809-16. doi: 10.2169/naika.98.809.
8
[Incretin-based therapy for treating patients with type 2 diabetes].
Orv Hetil. 2011 Nov 27;152(48):1931-40. doi: 10.1556/OH.2011.29238.
9
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845.
10
Choosing among the incretin agents and why it matters.
J Fam Pract. 2010 May;59(5 Suppl):S30-5.
Zotero 插件